The complaint states that the pharmacist inflated the costs of its injection for type 2 diabetes in order to subsidize a series of bribes to Optumrx.
Novo Nordisk is the objective, together with Optumrx, of a collective claim that claims a conspiracy to the shooting of the price of their diabetes medications.According to information published by Fiercebiotech, the complaint states that the pharmacist inflated the costs of its injection for type 2 diabetes in order to subsidize a series of bribes to Optumrx.
This demand, of more than 65 pages, affirms that the practice was one of the reasons why the price of injection, marketed under the name of Victaza, doubled between 2009 and 2017 from 400 dollars (358 euros) tomore than $ 900 (805 euros).
"We do not agree with the accusations, so we are prepared to strongly defend our company in this matter," said Ken Inchausti, communication director of Novo Nordisk.
On the other hand, the complaint also ensures that the aministration of pharmaceutical benefits (PBMS) says it is helping patients to obtain discounts, but then the amount of reimbursement is determined by the medicines to the medicines to the medicines.
In addition, the document states that PBMs use medicines discounts to exploit the prescription distribution system in the United States are used to profit from pharmacists.
